1. Medtech Insight
  2. >>Policy & Regulation

The Markets for Image-Guided Surgery: Location, Location...and Guidance

The market for image-guided surgical systems is worth $1.2 billion in 2005, according to a report recently issued by Medtech Insight, $1 billion attributable to interventional imaging, and $155.2 million to the sales of surgical navigation systems. The market is expected to experience a compound annual growth rate of 5.5% for the next several years, a slightly higher rate than the 4.1% forecast for the imaging industry as a whole.

The promise of image-guided surgery (IGS), according to "US Markets for Image-Guided Surgery Products," a report just out from Windhover Information's Medtech Insight division, has always been to improve the clinical utility and cost-effectiveness of chosen treatment protocols. The report defines the segment as any technologies that enable the intraoperative use of a representation of patient anatomy, obtained via either direct imaging techniques or computerized methods. Imaged-guided surgery has the potential to improve long-term patient outcomes, minimize surgical trauma, and reduce hospital-length-of stay, because precise targeting results in better removal of diseased tissues and minimal damage to adjacent tissue structures. For example, in arthroplasty procedures of the joint--a rapidly growing segment of the orthopedics industry--image guidance enables smaller tissue-destroying access incisions.

Overall, image-guided surgical systems have been slow to make inroads into the market. In a health care environment of cost...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

NAD Alerts Agendia Over Endorsing Physician’s Ties To Firm

 
• By Elizabeth Orr

The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 
• By Brian Bossetta

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.

Exact Sciences Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 
• By Natasha Barrow

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.